RARE CANCER RESEARCH FOUNDATION (EIN 463405526) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2013

Legal Domicile

Principal Officer

MARSHALL THOMPSON

Phone

9198278373

Tax Period

2023-01-01 to 2023-12-31

RARE CANCER RESEARCH FOUNDATION, founded in 2013, is a community nonprofit in the Medical Research sector that reported $3.5M in total revenue in fiscal year 2023. Revenue surged 9210% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.3M, a strong 38% operating margin.

Mission

THE RARE CANCER RESEARCH FOUNDATION IS DEDICATED TO CURING RARE CANCERS THROUGH STRATEGIC INVESTMENTS AND COLLABORATIONS THAT CATALYZE EFFECTIVE RESEARCH AND ACCELERATE DEPLOYMENT OF PROMISING THERAPIES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $2,606,409

Program Service Revenue $891,959

Investment Income $0

Other Revenue $5,592

TOTAL REVENUE $3,503,960

Expense Breakdown

Grants Paid $0

Salaries & Benefits $1,039,281

Fundraising Expenses $0

Program Expenses $1,527,627

Other Expenses $1,128,338

TOTAL EXPENSES $2,167,619

Year-over-Year Comparison

	2023	2022	Change
Revenue	$3,503,960	$37,638	+92.1%
Expenses	$2,167,619	$333,801	+5.5%
Net Income	$1,336,341	$-296,163	-5.5%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$321,090

Total Directors

$321,090

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MARSHALL THOMPSON	PRESIDENT	40.00	Officer Director	$189,251	$5,175	$194,426
AMBER SMITH	BIOBANK MANA	40.00	Highest	$136,717	$5,175	$141,892
BARBARA VAN HARE	PRES. OF PAT	40.00	Officer Director	$121,264	$5,400	$126,664
CHRIS HEERY	DIRECTOR	1.00	Officer Director	$0	$0	$0
MARK LAABS	FOUNDER & CH	15.00	Officer Director	$0	$0	$0
RYAN PRIPSTEIN	DIRECTOR	1.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$3,503,960	$2,167,619	$3,033,890	$1,336,341
2022	$37,638	$333,801	$757,505	$-296,163
2021	$1,072,853	$179,015	$1,051,579	$893,838
2020	$79,640	$183,429	$158,432	$-103,789
2019	$316,401	$246,863	$261,753	$69,538
2018	$347,745	$211,790	$194,013	$135,955

RARE CANCER RESEARCH FOUNDATION